drugset
drugset / Trial / NCT01751360

SYR-472 Open-label Study

NCT01751360 ↗

Phase 3 Completed 14 enrolled Takeda
Treatment

Summary

To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Timeline

Start
2013-04-01
Primary completion
2013-08-01
Completion
2013-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Trelagliptin Small molecule 100 mg —

Indications

diabetes mellitus